Delving into the Latest Updates on Yijielike (Shanghai) Biotechnology Co., Ltd. with Synapse

Overview

Tags

Digestive System Disorders

Infectious Diseases

Gene therapy

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

No Data

Disease Domain	Count

Infectious Diseases	1

Top 5 Drug Type	Count

Gene therapy	1

This study is an open-label, 2-Part (Single Ascending Dose [Part 1] And Dose Expansion) study that will evaluate the safety of EPI-003 administered to patients with chronic infection with HBV (CHB). EPI-003 is a liver-targeted antiviral therapeutic for intravenous (IV) injection that is capable of precise epigenetic modifications of the HBV genome without causing mutations in the gene sequence itself. This study is designed to determine the safety and pharmacokinetic (PK) and pharmacodynamic (PD) profile of EPI-003 in this patient population.

Start Date01 Dec 2024

Sponsor / Collaborator

Yijielike (Shanghai) Biotechnology Co., Ltd.

100 Clinical Results associated with Yijielike (Shanghai) Biotechnology Co., Ltd.

Login to view more data

0 Patents (Medical) associated with Yijielike (Shanghai) Biotechnology Co., Ltd.

Login to view more data

100 Deals associated with Yijielike (Shanghai) Biotechnology Co., Ltd.

Login to view more data

100 Translational Medicine associated with Yijielike (Shanghai) Biotechnology Co., Ltd.

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 18 Dec 2024

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Phase 1 Clinical

1

Login to view more data